IDBS has launched the IDBS Biomarker Discovery and Validation Solution, which streamlines biomarker research and improves collaboration, intellectual property management, and scientific understanding of complex disease, leading to new therapies.
The Biomarker Discovery and Validation Solution, based on the InforSense and E-WorkBook Suites, is the result of customer deployments with leading organisations such as Celera, Dana-Farber Cancer Institute and the Children’s Hospital of Philadelphia. The solution streamlines the speed and accuracy of biomarker research by enabling scientists to find, analyse and visualise complex phenotypic and genomic data. It provides multiple components supporting gene expression, genome wide association studies (GWAS) and proteomics techniques, which are packaged and deployed as web applications that guide scientists through quality control and analysis processes.
The Biomarker Discovery and Validation Solution enables scientists to find quickly and display all the latest relevant project data in one simple interface. Data sources can include live internal experimental results and external data provided by contract research organisations (CROs). Users can also upload their results and share them across multiple groups to improve data reuse.
Using the solution, scientists can quickly and easily 'slice-and-dice' clinical data to select subject cohorts and then move seamlessly into genomic quality control, analysis and integrated views. At each stage, users are guided through the required steps based on industry best practice, ensuring a consistent and repeatable approach to genomic analysis, all within an interactive web-based environment. Existing scripts, for example in R or PLINK, can be integrated into the environment, allowing the re-use of internal knowledge and capabilities. The IDBS solution also allows genes and proteins to be automatically annotated using public domain sources such as GenBank, UNI-PROT, GO and OMIM. It provides seamless integration to third-party systems such as metabolic pathway databases, as well as integration with external literature sources such as PubMed.
